Package leaflet information for the user
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
The dose is usually between 1-5 mg
Professional liability considerations may differ from those associated with FDA-approved medications, and providers should maintain comprehensive documentation of treatment rationale and patient consent
This effector protein becomes phosphorylated upon entry into the intracellular environment and is subsequently inserted into the apical membrane
For laboratories that need multiple Tesamorelin units rather than one individual product, the separate Tesamorelin x 10 Vials page provides a dedicated multi-vial procurement route
